Effect of icariin on ovarian cancer
Author Information
Author(s): Cao Shang-Mei, Chen Bo-Lin, Zou Zhen-Zhen, Yang Shao-Zhe, Fu Xiu-Hong
Primary Institution: Luohe Central Hospital, The First Affiliated Hospital of Luohe Medical College, Henan Key Laboratory of Fertility Protection and Aristogenesis, Shaoling District, Luohe, China
Hypothesis
This study aimed to explore the impact of icariin (ICA) on ovarian cancer (OC) and the underlying mechanisms.
Conclusion
The study revealed that ICA exhibited a specific impact on anti-tumor function outcomes in comparison to placebo, characterized by enhanced cell growth reduction and the induction of apoptosis.
Supporting Evidence
- ICA treatment was significantly correlated with reduced cell growth and induced apoptosis.
- Fourteen target genes were validated with success.
- The pathways involved in the therapeutic effect may be linked to cell apoptosis and anti-tumor mechanisms.
Takeaway
Icariin is a natural compound that can help fight ovarian cancer by making cancer cells grow slower and helping them die.
Methodology
The study used network pharmacology to identify ICA-targeted genes and pathways, followed by a systematic review and meta-analysis of in vitro studies.
Potential Biases
Publication bias was indicated, which might have inflated the reported therapeutic effects of ICA.
Limitations
The meta-analysis encompassed only in vitro experiments, and there is a paucity of research on the intersection genes, which could introduce bias.
Statistical Information
P-Value
p<0.00001
Confidence Interval
95% CI (−10.67, −4.92)
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website